Long QT syndrome (LQTs)-related miRNA (microribonucleic acid) and application thereof

A technology for QT syndrome, mir-3619, applied in DNA/RNA fragments, recombinant DNA technology, medical preparations containing active ingredients, etc.

Inactive Publication Date: 2016-03-09
NINGBO MEDICAL CENT LIHUILI HOSPITACL
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the prior art, there is no drug for the treatment of long QT syndrome that promotes hERG gene function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long QT syndrome (LQTs)-related miRNA (microribonucleic acid) and application thereof
  • Long QT syndrome (LQTs)-related miRNA (microribonucleic acid) and application thereof
  • Long QT syndrome (LQTs)-related miRNA (microribonucleic acid) and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0008] Materials and Methods

[0009] 1.1 Experimental instruments and reagents

[0010] 1.1.1 Main experimental instruments

[0011] Table 1 Names and manufacturers of experimental instruments

[0012]

[0013]

[0014] 1.1.2 Experimental drugs and reagents

[0015] Table 2 Names and manufacturers of experimental drugs

[0016]

[0017]

[0018] 1.1.3 Experimental method

[0019] real-time fluorescent quantitative PCR

[0020] Total RNA was extracted from transfected U2OS cells with Trizol reagent. The RNA was subsequently treated with sterile RNase-free, and the level of hERG gene mRNA was assessed using Taqman probes and detected by qRT-PCR. Primers and probes are from ABI company cat.#4331182 (number: Hs04234270-g1). Reverse transcription conditions were set as an initial step at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and a hold at 60°C for 1 min. Real-time PCR reactions were performed in triplicate independently. The results were anal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a molecular marker capable of prognosing long QT syndrome (LQTs) attack risks and diagnosing the LQTs, namely miRNA (microribonucleic acid)-3619, and an application of antisense oligonucleotides AMO-3619 of miRNA-3619 in preparation of medicines for treating the LQTs, mainly an application of the medicines in promotion of human ether-a-Go-Go related gene (hERG) functions. The molecular marker is characterized in that the medicine composition contains AMO-3619.

Description

technical field [0001] The present invention relates to the discovery of a miRNA that can predict the risk and diagnosis of long QT syndrome, that is, miR-3619, and the application of its antisense oligonucleotide AMO-3619 in the preparation of drugs for the treatment of long QT syndrome. Specifically, the present invention relates to the application of AMO-3619 in promoting the function of hERG gene in the preparation of drugs for treating long QT syndrome. Background technique [0002] Long QT syndrome (LongQTSyndrome, LQTs) refers to the prolonged QT interval and abnormal T wave on the electrocardiogram, prone to ventricular arrhythmia, especially Torsade de pointes (TdP), syncope and sudden death a group of syndromes. According to the etiology, it can be divided into congenital long QT syndrome (cLQTs) and acquired long QT syndrome (aLQTs). cLQTs are a major cause of episodic syncope and sudden unexpected death in children and young adults. A variety of channel gene m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12Q1/68A61K48/00A61K31/7105A61P9/06
Inventor 郑梅霞廉姜芳周建庆杨曦黄晓燕庄凯丽国建毛海燕巴艳娜方培亮
Owner NINGBO MEDICAL CENT LIHUILI HOSPITACL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap